Ensysce Biosciences, Inc. - Common Stock (ENSC)

Secures Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

SAN DIEGO, CA / ACCESS Newswire / March 5, 2025 / Ensysce Biosciences, Inc. (NASDAQENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced its participation in the 37th Annual ROTH Conference being held Sunday, March 16th to Tuesday, March 18th at the Laguna Cliffs Marriott Resort in Dana Point, CA.

~ Positive Enrollment Progress and Safety Data ~

~ Positive Phase 1b Data Confirms Overdose Protection for Highest Dosage Form of PF614-MPAR ~

~ FDA Breakthrough Therapy designation received for PF614-MPAR ~~ PF614-MPAR second clinical trial initiated ~~ Lead clinical candidate identified for OUD program ~~ PF614 Phase 3 trial poised to commence 1H 2025 ~

SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that on December 20, 2024, it received notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has demonstrated compliance with the minimum bid price requirement in Listing Rule 5550(a)(2). Ensysce had previously regained compliance with the stockholders' equity requirement in Listing Rule 5550(b)(1). As a result, the Company has met all requirements outlined in the Nasdaq Hearings Panel decision dated November 5, 2024, and Ensysce common stock will continue trading on The Nasdaq Capital Market.

~ Supply Chain Now Fully Secure for PF614-MPAR ~

~ $10 Million Commitment from Specialty Drug Manufacturer to Support Commercialization Efforts ~

~ Landmark Overdose Protection Clinical Trial of PF614-MPAR ~

SAN DIEGO, CA / ACCESSWIRE / December 3, 2024 / Ensysce Biosciences, Inc. (NASDAQENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that on Friday, December 6, 2024, effective at 12:01 a.m. Eastern Time, it will implement a 1-for-15 reverse split of its common stock. The Company's common stock will begin trading on a split-adjusted basis when the market opens on December 6, 2024, under its current trading symbol "ENSC". The new CUSIP number of the Company's common stock following the reverse stock split will be 293602 504.

Awarded $14 Million Multi-Year NIH Grant and Initiated Second Clinical Trial for Breakthrough Therapy PF614-MPAR

SAN DIEGO, CA / ACCESSWIRE / November 7, 2024 / Ensysce Biosciences, Inc. (NASDAQENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has received notice from The Nasdaq Stock Market ("Nasdaq") as described in a decision dated November 5, 2024, that the Company may continue its listing on The Nasdaq Capital Market tier with an extension to November 14, 2024, to demonstrate compliance with the equity requirement in Listing Rule 5550(b)(1) as of September 30, 2024, with filing of its Form 10-Q. Additionally, the Company received an extension toDecember 19, 2024, to evidence compliance with the Minimum Bid Price in Listing Rule 5550(a)(2), all other applicable requirements and the Company's satisfaction of certain other interim conditions.

~ Dr. Lynn Kirkpatrick to Present Latest Clinical Data for PF614 and PF614-MPAR ~

SAN DIEGO, CA / ACCESSWIRE / October 2, 2024 / Ensysce Biosciences, Inc. (NASDAQENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today provides a response from Chief Executive Officer, Dr. Lynn Kirkpatrick, regarding recent inquiries from stockholders and other interested parties.

~ New Data on Opioid Use Disorder Program at Society for Neuroscience Meeting ~

Phase 3 Study to Assess PF614 Efficacy in Treating Post-Surgical Pain

~ PF614 and PF614-MPAR Highlighted at Symposium on Severe Pain ~

Next Clinical Trial of FDA Breakthrough Therapy PF614-MPAR Supported by $14 Million Federal Government Grant

SAN DIEGO, CA / ACCESSWIRE / September 27, 2024 / Ensysce Biosciences, Inc. (NASDAQENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, has received notice from the listing qualifications department staff of The Nasdaq Stock Market ("Nasdaq") stating that the Company has not regained compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for the Company's common stock has remained below $1.00 per share through the initial 180-day compliance period ended September 23, 2024. The Company is not eligible for a second 180-day period because it does not comply with the minimum stockholders' equity requirement for initial listing on The Nasdaq Capital Market. The Nasdaq Hearings Panel will consider this matter in rendering a determination regarding the Company's continued listing on The Nasdaq Capital Market at an upcoming hearing which will also consider the Company's non-compliance with the $2.5 million stockholders' equity requirement set forth in Nasdaq Listing Rule 5550(b)(1).

SAN DIEGO, CA / ACCESSWIRE / August 29, 2024 / Ensysce Biosciences, Inc. (NASDAQENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has entered into definitive agreements, providing the Company with aggregate gross proceeds of $5 million, for the issuance and sale of an aggregate of 3,553,194 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.47 per share (or common stock equivalent in lieu thereof) in a registered direct offering. The Company also entered into definitive agreements to exercise certain outstanding warrants to purchase up to an aggregate of 7,203,504 shares of common stock of the Company originally issued in February 2024, having an exercise price of $1.06 per share, at a reduced exercise price of $0.47 per share. The shares of common stock issuable upon exercise of such outstanding warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-276537). In a concurrent private placement, the Company has also agreed to issue and sell unregistered Series A-3 warrants to purchase up to an aggregate of 14,358,450 shares of common stock and unregistered Series A-4 warrants to purchase up to an aggregate of 14,358,450 shares of common stock. The Series A-3 warrants and the Series A-4 warrants will have an exercise price of $0.47 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants. The Series A-3 warrants have a term of eighteen months from the date of stockholder approval and the Series A-4 warrants have a term of five years from the date of stockholder approval. The offerings are expected to close on or about August 29, 2024, subject to the satisfaction of customary closing conditions.

PF614-MPAR Progressing to Phase 1b Study to Verify Both Overdose Protection and Effective Delivery of OxycodoneOpioid Use Disorder Program Advances with Selection of PF9001 as Lead Drug Candidate PF614 Phase 3 Protocol Being Finalized for Submission to FDA

~ PF614 and PF614-MPAR Discussed in Satellite Symposium on Severe Pain ~

~ Ready to Commence PF614 Phase 3 Clinical Trial in 2024 ~

~ Dr. Lynn Kirkpatrick, CEO, to Introduce Satellite Symposium on Severe Pain: A New Chapter for Safer Analgesics ~

~ Geoff Birkett, Chief Commercial Officer, Provides Insight Following EPHMRA Meeting ~